| Similar Articles |
|---|
 |
The Motley Fool
October 14, 2010
Matt Koppenheffer |
Cell Therapeutics' Shares Popped: What You Need to Know Shares of biopharma specialist Cell Therapeutics leapt more than 16% today on huge volume.   |
The Motley Fool
September 15, 2010
Brian Orelli |
Cell Therapeutics Goes for Broke If Cell Therapeutics can't get new funding soon, long-term consequences may be the least of its worries; time on the clock looks to be running out. |
The Motley Fool
July 29, 2011
Sean Williams |
Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling. |
The Motley Fool
June 15, 2011
Brian Orelli |
Investors Need a Peephole Into FDA Offices Cell Therapeutics is gung ho about its resubmission, but investors only get one side of the story. |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
December 31, 2011
David Williamson |
2011 Review: Cell Therapeutics After starting the year at a split-adjusted $2.22 a share, Cell Therapeutics stock lost almost 50% of its value by the end of December, closing at $1.16. How did we get here? |
The Motley Fool
June 15, 2005
Brian Gorman |
Cell Therapeutics' Gamble The biotech company's struggles are far from over. Without an approved drug on the market or the certainty of FDA clearance, the firm won't have an easy time finding investors. |
The Motley Fool
July 20, 2010
Jordan DiPietro |
Cell Therapeutics Finds a New Home The company signs a long-term agreement with an Italian manufacturer for a lymphoma treatment. |
The Motley Fool
May 4, 2011
Brian Orelli |
Cell Therapeutics: Denied but Not Rejected Cell Therapeutics' ball may be headed for the end zone, but the FDA has an eight-foot free safety ready to bat it down. |
The Motley Fool
September 17, 2010
Luke Timmerman |
Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders? |
The Motley Fool
December 3, 2010
Travis Hoium |
Orexigen Therapeutics Shares Plunged: What You Need to Know Shares of biopharmaceutical company Orexigen Therapeutics fell 10% today after a Food and Drug Administration announcement. |
The Motley Fool
July 1, 2011
Brian Orelli |
What Will Cell Therapeutics Do With Your Money? Unfortunately the answer is probably, "buying a drug." |
The Motley Fool
September 28, 2011
Brian Orelli |
One Step Closer to an FDA Decision Cell Therapeutics is still risky, though. |
The Motley Fool
January 4, 2012
Brian Orelli |
Mark Your Calendars, Biotech Investors Cell Therapeutics' advisory panel meet ought to be entertaining. |
The Motley Fool
April 14, 2008
Brian Orelli |
Stem Cells Show Off The FDA moves closer to setting up stem cell clinical trials, setting guidelines that put treatment safety first and foremost. |
The Motley Fool
January 28, 2011
Brian Orelli |
Value Investing, Biotech Style Biotech investors should regard every binary event as a varying degree of confidence in a positive or negative result. |
The Motley Fool
December 11, 2007
Brian Orelli |
Medicare Whacks Oncology Drugs Bad news for some pharmaceutical companies as Medicare announces it is reducing the reimbursement rate for two lymphoma drugs. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
May 28, 2009
Robert Steyer |
Fighting an Incurable Disease United Therapeutics battles drug giants in a specialized blood-pressure treatment arena. |
The Motley Fool
August 24, 2011
Brian D. Pacampara |
United Therapeutics Shares Got Crushed: What You Need to Know Shares of drugmaker United Therapeutics plunged 17% today after its experimental orally administered lung drug failed in a late-stage clinical trial. |
Registered Rep.
February 1, 2005
Bob Hirschfeld |
Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street. |
The Motley Fool
July 30, 2010
Anand Chokkavelu |
5 Stocks to Consider Before Buying Pfizer If you like Pfizer, you may like these five insurance and medical stocks better. |
The Motley Fool
July 13, 2011
David Williamson |
Roundtable: The Biggest Risks in Biotech Three biotech companies to steer clear of. |
The Motley Fool
July 27, 2010
Brian Orelli |
Better Buy: Cell Therapeutics or Sequenom? Which one deserves your dollars more? |
The Motley Fool
September 17, 2010
Anders Bylund |
Would a Reverse Split Help These Stocks? A reverse split seems to cure many problem stocks, but that's not always good enough. |
The Motley Fool
July 26, 2010
Tom Gardner |
A Disaster for Shareholders Two biotechnology stocks not worth the trouble. |
The Motley Fool
March 21, 2007
Brian Lawler |
New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary. |
The Motley Fool
May 29, 2007
Brian Lawler |
The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids. |
The Motley Fool
November 10, 2005
W.D. Crotty |
Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%. |
The Motley Fool
November 13, 2009
Brian Orelli |
Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
The Motley Fool
December 9, 2011
David Williamson |
1 Biotech Soars While Another Crashes Cell Therapeutics dilutes shareholders while SIGA squashes fears. |
The Motley Fool
October 10, 2005
Stephen D. Simpson |
The FDA: Boon, Bane, Whipping Boy Everyone wants the FDA to be faster, better, and cheaper, but that may not be a credible expectation. Investors would do well to keep an eye on the FDA because its policies and pressures ultimately filter down to our medicine cabinets, wallets, and portfolios. |
The Motley Fool
January 10, 2011
James Royal |
Hit the Jackpot With These 7 Stocks These stocks have attracted enormous interest from investors, perhaps because many of the shares trade hands at just pennies a share. |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
The Motley Fool
August 2, 2004
Charly Travers |
What's a Drug Worth? The value of small biotech companies is in their investigational drug programs. |
AskMen.com
Dave Golokhov |
Cell Phones And Cancer With so much money in the cell phone industry, it looks like straight answers regarding the risks will be hard to come by. |
AskMen.com
Joshua Levine |
Selling Your Body To Science Have you ever thought about the number of voluntary patients who basically sell their bodies to clinical trials in the name of science? Well, the number is staggering and it can reach well into the thousands. The main reason being the large paycheck that comes with the job. |
The Motley Fool
March 30, 2005
David Nierengarten |
Soothing Results, But Pain for Investors Pain Therapeutics delivers again but its stock barely budged. What gives? |
AskMen.com
Jacob Franek |
Do Cell Phones Cause Cancer? The cellular phone is fast becoming the single most important piece of personal electronics - but at what cost and do cell phones cause brain cancer? |
The Motley Fool
November 1, 2006
John Reeves |
7 More Surprising 1-Star Stocks Can these stocks keep up the momentum? New River Pharmaceuticals... Acorda Therapeutics... NVE... American Power Conversion... etc. |
The Motley Fool
October 26, 2009
Adam J. Wiederman |
Time to Sell and Lock in Your Gains With stocks up so much, it might be time to take some money off the table. |
